Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Aura Biosciences in a report released on Wednesday, May 28th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.96) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($1.92) EPS.
A number of other brokerages have also recently issued reports on AURA. Citigroup restated an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. JMP Securities restated a "market outperform" rating and set a $19.00 target price on shares of Aura Biosciences in a report on Friday, May 23rd. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $22.00.
View Our Latest Stock Analysis on AURA
Aura Biosciences Trading Up 3.7%
Aura Biosciences stock traded up $0.21 during mid-day trading on Friday, hitting $6.07. The stock had a trading volume of 108,590 shares, compared to its average volume of 206,689. Aura Biosciences has a 12 month low of $4.35 and a 12 month high of $12.38. The stock has a market capitalization of $305.33 million, a PE ratio of -3.51 and a beta of 0.43. The stock has a 50-day simple moving average of $5.63 and a two-hundred day simple moving average of $7.20.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08).
Insider Transactions at Aura Biosciences
In other news, Director David Michael Johnson bought 20,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The shares were acquired at an average price of $4.90 per share, with a total value of $98,000.00. Following the transaction, the director now owns 166,167 shares in the company, valued at $814,218.30. This represents a 13.68% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anthony S. Gibney bought 50,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was purchased at an average cost of $4.90 per share, for a total transaction of $245,000.00. Following the transaction, the insider now owns 58,452 shares in the company, valued at $286,414.80. The trade was a 591.58% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 9,578 shares of company stock valued at $52,067 over the last 90 days. 5.40% of the stock is owned by company insiders.
Institutional Investors Weigh In On Aura Biosciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Long Focus Capital Management LLC increased its position in shares of Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Levin Capital Strategies L.P. grew its holdings in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock valued at $10,255,000 after buying an additional 783,984 shares in the last quarter. Acorn Capital Advisors LLC acquired a new position in Aura Biosciences in the 1st quarter valued at $3,460,000. B Group Inc. bought a new stake in shares of Aura Biosciences during the 4th quarter valued at $3,885,000. Finally, Regency Capital Management Inc. DE raised its position in shares of Aura Biosciences by 23.0% in the 1st quarter. Regency Capital Management Inc. DE now owns 749,482 shares of the company's stock valued at $4,392,000 after buying an additional 140,058 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
See Also
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
